|
1
|
Venkata V and Irulandy P: The frequency
and distribution pattern of minor salivary gland tumors in a
government dental teaching hospital, Chennai, India. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod. 111:e32–e39. 2011. View Article : Google Scholar
|
|
2
|
Schwarz S, Stiegler C, Müller M, Ettl T,
Brockhoff G, Zenk J and Agaimy A: Salivary gland mucoepidermoid
carcinoma is a clinically, morphologically and genetically
heterogeneous entity: A clinicopathological study of 40 cases with
emphasis on grading, histological variants and presence of the
t(11;19) translocation. Histopathology. 58:557–570. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Birkeland AC, Foltin SK, Michmerhuizen NL,
Hoesli RC, Rosko AJ, Byrd S, Yanik M, Nor JE, Bradford CR, Prince
ME, et al: Correlation of Crtc1/3-Maml2 fusion status, grade and
survival in mucoepidermoid carcinoma. Oral Oncol. 68:5–8. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rapidis AD, Givalos N, Gakiopoulou H,
Stavrianos SD, Faratzis G, Lagogiannis GA, Katsilieris I and
Patsouris E: Mucoepidermoid carcinoma of the salivary glands.
Review of the literature and clinicopathological analysis of 18
patients. Oral Oncol. 43:130–136. 2007. View Article : Google Scholar
|
|
5
|
Green B, Rahimi S and Brennan PA: Salivary
gland malignancies-an update on current management for oral
healthcare practitioners. Oral Dis. 22:735–739. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan HK and Ismail S: Side effects of
chemotherapy among cancer patients in a Malaysian General Hospital:
Experiences, perceptions and informational needs from clinical
pharmacists. Asian Pac J Cancer Prev. 15:5305–5309. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thomas LW, Lam C and Edwards SW: Mcl‑1;
the molecular regulation of protein function. FEBS Lett.
584:2981–2989. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Senichkin VV, Streletskaia AY, Zhivotovsky
B and Kopeina GS: Molecular comprehension of Mcl-1: From gene
structure to cancer therapy. Trends Cell Biol. 29:549–562. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Opferman JT, Letai A, Beard C, Sorcinelli
MD, Ong CC and Korsmeyer SJ: Development and maintenance of B and T
lymphocytes requires antiapoptotic MCL‑1. Nature. 426:671–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sieghart W, Losert D, Strommer S, Cejka D,
Schmid K, Rasoul‑Rockenschaub S, Bodingbauer M, Crevenna R, Monia
BP, Peck‑Radosavljevic M and Wacheck V: Mcl-1 overexpression in
hepatocellular carcinoma: A potential target for antisense therapy.
J Hepatol. 44:151–157. 2006. View Article : Google Scholar
|
|
11
|
Campbell KJ, Dhayade S, Ferrari N, Sims
AH, Johnson E, Mason SM, Dickson A, Ryan KM, Kalna G, Edwards J, et
al: MCL-1 is a prognostic indicator and drug target in breast
cancer. Cell Death Dis. 9:192018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin J, Fu D, Dai Y, Lin J and Xu T: Mcl-1
inhibitor suppresses tumor growth of esophageal squamous cell
carcinoma in a mouse model. Oncotarget. 8:114457–114462. 2017.
View Article : Google Scholar
|
|
13
|
Gény C, Rivière G, Bignon J, Birlirakis N,
Guittet E, Awang K, Litaudon M, Roussi F and Dumontet V: Anacardic
acids from knema hookeriana as modulators of Bcl‑xL/Bak and
Mcl‑1/Bid interactions. J Nat Prod. 79:838–844. 2016. View Article : Google Scholar
|
|
14
|
Choi ES, Kim JS, Kwon KH, Kim HS, Cho NP
and Cho SD: Methanol extract of Sanguisorba officinalis L. with
cytotoxic activity against PC3 human prostate cancer cells. Mol Med
Rep. 6:670–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Clohessy JG, Zhuang J, de Boer J,
Gil‑Gómez G and Brady HJ: Mcl‑1 interacts with truncated Bid and
inhibits its induction of cytochrome c release and its role in
receptor-mediated apoptosis. J Biol Chem. 281:5750–5759. 2006.
View Article : Google Scholar
|
|
16
|
Bolaños JP, Moro MA, Lizasoain I and
Almeida A: Mitochondria and reactive oxygen and nitrogen species in
neurological disorders and stroke: Therapeutic implications. Adv
Drug Deliv Rev. 61:1299–1315. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen
M and Wang Y: Oridonin induces apoptosis, inhibits migration and
invasion on highly-metastatic human breast cancer cells. Am J Chin
Med. 41:177–196. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang IH, Shin JA, Lee KE, Kim J, Cho NP
and Cho SD: Oridonin induces apoptosis in human oral cancer cells
via phosphorylation of histone H2AX. Eur J Oral Sci. 125:438–443.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin S, Shen JN, Wang J, Huang G and Zhou
JG: Oridonin induced apoptosis through Akt and MAPKs signaling
pathways in human osteosarcoma cells. Cancer Biol Ther. 6:261–268.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera
S and Ikejima T: Oridonin induces G2/M arrest and apoptosis via
activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK
survival pathway in murine fibrosarcoma L929 cells. Arch Biochem
Biophys. 490:70–75. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM,
Ren Z, Li XM, Shen HM and Zeng HT: Oridonin induces apoptosis via
PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta
Pharmacol Sin. 28:1819–1826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu J, Chen X, Qu S, Yao B, Xu Y, Wu J, Jin
Y and Ma C: Oridonin induces G2/M cell cycle arrest and
apoptosis via the PI3K/Akt signaling pathway in hormone-independent
prostate cancer cells. Oncol Lett. 13:2838–2846. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Zhu L, Feng X, Zhang H, Luo Q and
Chen F: Oridonin induces G2/M cell cycle arrest and apoptosis in
human oral squamous cell carcinoma. Eur J Pharmacol. 815:282–289.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li S, Shi D, Zhang L, Yang F and Cheng G:
Oridonin enhances the radiosensitivity of lung cancer cells by
upregulating Bax and downregulating Bcl‑2. Exp Ther Med.
16:4859–4864. 2018.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real‑time quantitative PCR and
the 2(‑Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Tait SW and Green DR: Mitochondria and
cell death: Outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Akgul C: Mcl-1 is a potential therapeutic
target in multiple types of cancer. Cell Mol Life Sci.
66:1326–1336. 2009. View Article : Google Scholar
|
|
28
|
Maji S, Samal SK, Pattanaik L, Panda S,
Quinn BA, Das SK, Sarkar D, Pellecchia M, Fisher PB and Dash R:
Mcl-1 is an important therapeutic target for oral squamous cell
carcinomas. Oncotarget. 6:16623–16637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin JA, Jung JY, Ryu MH, Safe S and Cho
SD: Mithramycin A inhibits myeloid cell leukemia-1 to induce
apoptosis in oral squamous cell carcinomas and tumor xenograft
through activation of Bax and oligomerization. Mol Pharmacol.
83:33–41. 2013. View Article : Google Scholar
|
|
30
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wei SH, Dong K, Lin F, Wang X, Li B, Shen
JJ, Zhang Q, Wang R and Zhang HZ: Inducing apoptosis and enhancing
chemosensitivity to gemcitabine via RNA interference targeting
Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother
Pharmacol. 62:1055–1064. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Muller F, Cerella C, Radogna F, Dicato M
and Diederich M: Effects of natural products on Mcl-1 expression
and function. Curr Med Chem. 22:3447–3461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Won DH, Chung SH, Shin JA, Hong KO, Yang
IH, Yun JW and Cho SD: Induction of sestrin 2 is associated with
fisetin‑mediated apoptosis in human head and neck cancer cell
lines. J Clin Biochem Nutr. 64:97–105. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee HE, Choi ES, Shin JA, Lee SO, Park KS,
Cho NP and Cho SD: Fucoidan induces caspase-dependent apoptosis in
MC3 human mucoepidermoid carcinoma cells. Exp Ther Med. 7:228–232.
2014. View Article : Google Scholar
|
|
36
|
Zhang HP, Li GQ, Guo WZ, Chen GH, Tang HW,
Yan B, Li J, Zhang JK, Wen PH, Wang ZH, et al: Oridonin
synergistically enhances JQ1-triggered apoptosis in hepatocellular
cancer cells through mitochondrial pathway. Oncotarget.
8:106833–106843. 2017. View Article : Google Scholar :
|
|
37
|
Ikezoe T, Yang Y, Bandobashi K, Saito T,
Takemoto S, Machida H, Togitani K, Koeffler HP and Taguchi H:
Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits
the proliferation of cells from lymphoid malignancies in
association with blockade of the NF‑kappa B signal pathways. Mol
Cancer Ther. 4:578–586. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Roy MJ, Vom A, Czabotar PE and Lessene G:
Cell death and the mitochondria: Therapeutic targeting of the BCL‑2
family‑driven pathway. Br J Pharmacol. 171:1973–1987. 2014.
View Article : Google Scholar :
|
|
39
|
Liu JJ, Huang RW, Lin DJ, Wu XY, Peng J,
Pan XL, Lin Q, Hou M, Zhang MH and Chen F: Antiproliferation
effects of oridonin on HPB‑ALL cells and its mechanisms of action.
Am J Hematol. 81:86–94. 2006. View Article : Google Scholar : PubMed/NCBI
|
